CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***]”, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.Waiver, Confirmation and Agreement Regarding Research Collaboration Agreement • March 28th, 2024 • Omega Therapeutics, Inc. • Biological products, (no disgnostic substances)
Effective December 31, 2023 Omega Therapeutics, Inc. Cambridge, Massachusetts 02141 Re: Waiver, Confirmation and Agreement Regarding Research Collaboration Agreement Ladies and Gentlemen:Waiver, Confirmation and Agreement Regarding Research Collaboration Agreement • March 28th, 2024 • Omega Therapeutics, Inc. • Biological products, (no disgnostic substances)
Reference is made to the Patent License Agreement (Co-Exclusive) between Whitehead Institute for Biomedical Research (“Whitehead”) and Omega Therapeutics, Inc. (“Omega”) effective as of May 22, 2019 (the “Co-Exclusive License Agreement”; Whitehead Ref: L7516). Capitalized terms used in this letter agreement (this “Letter”) without definition shall have the meanings given to them in the Co-Exclusive License Agreement. All references to Sections herein are to Sections in the Co-Exclusive License Agreement unless otherwise stated.
